Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee.
We have measured plasma and synovial fluid concentrations of meclofenamic acid at 2, 4, 8, and 12 h during steady-state administration (100 mg three times daily for 4-7 days). Paired plasma and synovial samples were obtained pre-treatment and at one of the above times in twelve patients with a diagnosis of rheumatoid arthritis. In addition, the extent of protein binding of meclofenamic acid was assessed in vitro in the pre-treatment plasma and synovial fluid specimens. Peak total concentrations of 1.73 and 0.86 micrograms.ml-1 were observed in plasma (at 2 h) and synovial fluid (at 4 h) respectively. The extent of protein binding was 99.7 and 99.6% (not significantly different) in plasma and synovial fluid respectively. The results of this study are compared to those from similar reported studies of other nonsteroidal anti-inflamatory compounds.
Koup
J R
JR
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, MI.
Thomas
D
D
Tucker
E
E
Black
A
A
Ruderman
M
M
Dixon
J A
JA
Kinkel
A
A
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D007719:Knee Joint; D008297:Male; D008469:Meclofenamic Acid / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood; D008875:Middle Aged; D011485:Protein Binding; D013582:Synovial Fluid / Q000032:analysis*; D062367:ortho-Aminobenzoates / Q000032:analysis*
D062367:ortho-Aminobenzoates; D008469:Meclofenamic Acid